These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 22384627)

  • 1. [Usefulness of osteopontin (OPN) determinations in ovarian cancer patients who underwent first-line chemotherapy].
    Mrochem-Kwarciak J; Mrochen-Domin I; Wojcieszek A; Deja R; Chmura A; Masłyk B; Nowara E; Kaleta B; Kołosza Z; Bartnik W
    Ginekol Pol; 2011 Dec; 82(12):911-7. PubMed ID: 22384627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of selected serum protein markers as early detectors of ovarian cancer].
    Mrochem J; Sodowski K; Deja R; Walaszek-Gruszka A; Wojcieszek A; Kołosza Z; Chmura A; Czernik E; Masłyk B; Bartnik W; Cnota W
    Ginekol Pol; 2008 Apr; 79(4):271-5. PubMed ID: 18592865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic values of osteopontin combined with CA125 for ovarian cancer: a meta-analysis.
    Lan Z; Fu D; Yu X; Xi M
    Fam Cancer; 2016 Apr; 15(2):221-30. PubMed ID: 26458935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of osteopontin in differential diagnosis of ovarian tumors.
    Moszynski R; Szubert S; Szpurek D; Michalak S; Sajdak S
    J Obstet Gynaecol Res; 2013 Nov; 39(11):1518-25. PubMed ID: 23875677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of osteopontin and CA125 in detection of epithelial ovarian carcinoma.
    Milivojevic M; Boskovic V; Atanackovic J; Milicevic S; Razic S; Kotlica BK
    Eur J Gynaecol Oncol; 2013; 34(1):83-5. PubMed ID: 23590008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer.
    Nakae M; Iwamoto I; Fujino T; Maehata Y; Togami S; Yoshinaga M; Douchi T
    J Obstet Gynaecol Res; 2006 Jun; 32(3):309-14. PubMed ID: 16764622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer.
    Schorge JO; Drake RD; Lee H; Skates SJ; Rajanbabu R; Miller DS; Kim JH; Cramer DW; Berkowitz RS; Mok SC
    Clin Cancer Res; 2004 May; 10(10):3474-8. PubMed ID: 15161704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Plasma Osteopontin Levels between Patients with Borderline Ovarian Tumours and Serous Ovarian Carcinoma.
    Živný JH; Leahomschi S; Klener P; Živný J; Haluzík M; Cibula D
    Folia Biol (Praha); 2016; 62(6):258-262. PubMed ID: 28189149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer.
    Brakora KA; Lee H; Yusuf R; Sullivan L; Harris A; Colella T; Seiden MV
    Gynecol Oncol; 2004 May; 93(2):361-5. PubMed ID: 15099946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy.
    Tuxen MK; Sölétormos G; Dombernowsky P
    Br J Cancer; 2001 May; 84(10):1301-7. PubMed ID: 11355938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of beta1,4-galactosyltransferase as a potential biomarker for the detection of subclinical disease after the completion of primary therapy for ovarian cancer.
    Odunsi K; Ghamande S; Chandrasekaran EV; Ta A; Moysich KB; Driscoll D; Matta K; Lele S
    Am J Obstet Gynecol; 2002 Sep; 187(3):575-80. PubMed ID: 12237630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma.
    Hollevoet K; Nackaerts K; Gosselin R; De Wever W; Bosquée L; De Vuyst P; Germonpré P; Kellen E; Legrand C; Kishi Y; Delanghe JR; van Meerbeeck JP
    J Thorac Oncol; 2011 Nov; 6(11):1930-7. PubMed ID: 21841505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic markers for early detection of ovarian cancer.
    Visintin I; Feng Z; Longton G; Ward DC; Alvero AB; Lai Y; Tenthorey J; Leiser A; Flores-Saaib R; Yu H; Azori M; Rutherford T; Schwartz PE; Mor G
    Clin Cancer Res; 2008 Feb; 14(4):1065-72. PubMed ID: 18258665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of osteopontin expression in cervical cancer.
    Cho H; Hong SW; Oh YJ; Kim MA; Kang ES; Lee JM; Kim SW; Kim SH; Kim JH; Kim YT; Lee K
    J Cancer Res Clin Oncol; 2008 Aug; 134(8):909-17. PubMed ID: 18210151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential markers that complement expression of CA125 in epithelial ovarian cancer.
    Rosen DG; Wang L; Atkinson JN; Yu Y; Lu KH; Diamandis EP; Hellstrom I; Mok SC; Liu J; Bast RC
    Gynecol Oncol; 2005 Nov; 99(2):267-77. PubMed ID: 16061277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer.
    Piatek S; Panek G; Lewandowski Z; Bidzinski M; Piatek D; Kosinski P; Wielgos M
    J Ovarian Res; 2020 Sep; 13(1):102. PubMed ID: 32878632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements.
    Czekierdowski A
    Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):113-31. PubMed ID: 12898913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of Ca 125 levels during primary therapy.
    Markmann S; Gerber B; Briese V
    Anticancer Res; 2007; 27(4A):1837-9. PubMed ID: 17649781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.